# France Dry Age Related Macular Degeneration Market

> France Dry Age-Related Macular Degeneration (AMD) Market Research Report: Size, Share, Trend Analysis By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group (Above 75 years, Above 60 years, Above 40 years), By Diagnosis and Treatment (Treatment, Diagnosis), By Route of Administration (Oral, Injectables) and By End Userss (Hospitals Clinics, Diagnostic Centers, Academic Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.52%
- **2024:** $ 239.9 Million
- **2025:** $ 259.81 Million
- **2035:** $ 532.73 Million
- **Key Players:** Novartis (FR), Roche (FR), Regeneron Pharmaceuticals (FR), Bayer (FR), Allergan (FR), Apellis Pharmaceuticals (FR), Santen Pharmaceutical (FR), Horizon Therapeutics (FR)

**Report ID:** MRFR/MED/43218-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/france-dry-age-related-macular-degeneration-market-44898

---

## Market Summary

## **France Dry Age-Related Macular Degeneration (AMD) Market Overview**

As per MRFR analysis, the France Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 187.0 (USD Million) in 2023. The France Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 204.0(USD Million) in 2024 to 487.0 (USD Million) by 2035. The France Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 8.232% during the forecast period (2025 - 2035).

**Key France Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted**

In France, the Dry Age-Related Macular Degeneration (AMD) market is witnessing significant trends driven by an aging population and increasing awareness of eye health. The French government has acknowledged the growing prevalence of AMD, which is one of the leading causes of visual impairment among older adults. With nearly a quarter of the population projected to be over 60 by 2030, this demographic shift is pushing healthcare providers and stakeholders to focus on effective AMD management and care solutions. 

The healthcare system in France, known for its universal coverage, is adapting to address the needs of those affected by this condition, including expanded access to ophthalmological care and preventive strategies.The evolving treatment options and new technologies, such as telemedicine, are creating opportunities in the French market. Telemedicine is enhancing access to physician consultations, especially in rural areas. Emerging therapies, including nutraceuticals and drug treatments, are also becoming popular as patients look for ways to manage their condition.

In addition, collaboration among pharmaceutical companies and research institutions is increasing in France for the development of more effective treatment modalities and clinical trials, which could foster better patient outcomes. Recently, there has been an observable shift towards supporting and educating patients in France.

As the understanding of AMD becomes more widespread, initiatives focusing on lifestyle modifications and diet are being promoted to help reduce the risk of progression. Eye health screenings are becoming more routine, with the government actively encouraging regular check-ups. This increasing emphasis on proactive health management, along with government support for AMD research, signifies a dynamic shift in how AMD is viewed and treated in France, paving the way for future progress in this market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**France Dry Age-Related Macular Degeneration (AMD) Market Drivers**

**Increasing Aging Population in France**

The aging population in France is a significant driver for the France Dry Age-Related Macular Degeneration (AMD) Market Industry. According to the French National Institute of Statistics and Economic Studies, the proportion of people aged 65 and older in France is projected to rise from 18% in 2020 to around 23% by 2030.

This demographic shift focuses the health system on age-related conditions, including AMD, which primarily affects older adults.Increased public awareness campaigns led by organizations like France Retinopathies reinforce the need for treatment and management of AMD, pushing the market's growth as healthcare services respond to the rising patient population. Such a growing demographic indicates an increasing demand for therapies and technologies catering to AMD, making it a pivotal market driver.

**Advancements in AMD Treatment Technologies**

Technological advancements in the treatment and management of Dry Age-Related Macular Degeneration (AMD) are propelling the France Dry Age-Related Macular Degeneration (AMD) Market Industry forward. Innovative treatments, such as new-generation anti-VEGF therapies and gene therapies, have shown promising results in clinical trials and are gaining traction in administrative health bodies. The French Ministry of Health has been actively promoting research and development in ocular treatments through funding programs, enabling faster patient access to advanced therapies.As a result, the market is expected to witness increased investments, driving overall growth.

With 25 new drugs expected to be authorized for AMD in the coming years, there is significant optimism for enhanced treatment outcomes.

**Rising Awareness and Screening Programs for AMD**

The rising awareness and comprehensive screening programs for Dry Age-Related Macular Degeneration (AMD) are significantly influencing the France Dry Age-Related Macular Degeneration (AMD) Market Industry. Various health campaigns, such as those launched by the French Ophthalmology Society, emphasize the importance of early detection and lifestyle modifications to mitigate AMD risks.

By advocating for regular eye examinations, these initiatives are leading to higher rates of diagnosis, which in turn drives demand for treatment options.A reported increase in AMD diagnoses by approximately 30% over five years correlates with these awareness efforts, showing a direct effect on market growth as more patients seek therapeutic interventions.

**Government Initiatives to Enhance Eye Care Accessibility**

Government initiatives in France aimed at enhancing accessibility to eye care services play a crucial role in the growth prospects of the France Dry Age-Related Macular Degeneration (AMD) Market Industry. The French government, through its National Health Strategy, recognizes the urgency of addressing visual impairments as a significant health issue and has thus invested in subsidizing eye care services for lower-income populations.

This inclusive approach is expected to significantly increase the number of patients receiving care for AMD, as evidenced by a projected 15% rise in the number of funded eye care appointments by 2025.Such government backing underscores potential market growth by creating access points for patients who may otherwise neglect their AMD symptoms.

**France Dry Age-Related Macular Degeneration (AMD) Market Segment Insights**

**Dry Age-Related Macular Degeneration (AMD) Market Stage Insights**

The France Dry Age-Related Macular Degeneration (AMD) Market, particularly within the Stage segment, plays a crucial role in understanding the progression and treatment of this condition. The market is characterized by three primary stages of AMD: early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration. Early age-related macular degeneration is often the most common stage, where patients may not experience significant vision loss, but there is a growing awareness about the importance of early detection and lifestyle interventions to prevent progression.

This stage primarily attracts the attention of healthcare providers as educational campaigns and screening programs aim to address risk factors such as smoking, obesity, and diet. Intermediate age-related macular degeneration represents a stage where patients begin to experience noticeable changes in vision, making monitoring and appropriate management essential to mitigate risks.

This stage is essential for identifying patients who may transition to the more severe late age-related macular degeneration stage, which significantly impacts daily activities.Late age-related macular degeneration is marked by severe vision impairment and poses substantial challenges to patients' quality of life, making it a focal point for innovative treatments and healthcare strategies. 

The progress of treatments in the France Dry Age-Related Macular Degeneration (AMD) Market has sparked increased interest from both pharmaceutical companies and healthcare providers, leading to the development of novel therapies aimed at managing symptoms and slowing disease progression across all stages.

The segmentation of these stages not only aids in targeted research and healthcare initiatives but also helps in understanding market growth dynamics as more individuals enter the aging population in France, which, according to statistics, is on the rise.With the shift towards preventive care and the emphasis on early diagnosis, the France Dry Age-Related Macular Degeneration (AMD) Market segmentation becomes increasingly important, guiding both public health strategies and clinical practices in addressing this common age-related condition.

As the healthcare ecosystem in France continues to evolve, the focus on each stage within this segment underscores the importance of tailored approaches and interventional strategies to improve outcomes for patients across the spectrum of age-related macular degeneration.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights**

The France Dry Age-Related Macular Degeneration (AMD) Market is significantly influenced by the Age Group of its population, particularly focusing on individuals over the age of 40, with heightened prevalence in those above 60 and 75 years. The aging population in France contributes to a rising incidence of AMD, which is largely driven by lifestyle factors, dietary habits, and increased life expectancy.

Those above 75 years, often faced with multiple health issues, are particularly vulnerable to AMD, emphasizing the need for targeted healthcare services and interventions.This age group holds a substantial share of the market, as a significant number of individuals experience vision impairment or loss associated with this condition. 

The group aged over 60 years also experiences a noticeable impact, with many individuals becoming increasingly aware of preventive measures and treatments for AMD, thus creating a substantial opportunity for various market players. The market reflects a growing trend for innovative therapies and solutions to address AMD, especially among older demographics, signaling a surge in demand for specialized products and services tailored to these age groups, thereby impacting France Dry Age-Related Macular Degeneration (AMD) Market data significantly.

**Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights**

The Diagnosis and Treatment segment of the France Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in the management of this ocular condition, which affects a significant portion of the elderly population in France. Given that the incidence of AMD is increasing with an aging demographic, effective diagnosis and treatment options are essential. Diagnosis often includes advanced imaging techniques that facilitate early detection, thus improving treatment outcomes. 

The treatment landscape is evolving, with various therapeutic approaches catering to the needs of patients.This segment tends to dominate due to the necessity of timely interventions to slow disease progression and preserve vision, which is vital for maintaining the quality of life for affected individuals. Numerous innovations in treatment protocols, alongside ongoing research, are expected to drive advancements further in this area.

The landscape is supported by health policies emphasizing preventive care and access to ophthalmological services, aligning with France's commitment to improving its healthcare system and addressing age-related diseases.Overall, the Diagnosis and Treatment segment represents a critical aspect of the France Dry Age-Related Macular Degeneration (AMD) Market, positioning itself as a significant contributor to market growth and advancements in patient care.

**Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights**

The Route of Administration segment in the France Dry Age-Related Macular Degeneration (AMD) Market is critical as it significantly influences treatment options and patient adherence. This market comprises various methods, prominently featuring oral and injectable forms of therapy. Oral medications offer convenience and ease of use, potentially enhancing patient compliance due to their non-invasive nature.

Conversely, injectables, which are essential for delivering precise doses directly into the eye, underscore their importance in managing more severe forms of AMD effectively.The injectables are often favored in clinical practice for their rapid action and effectiveness in controlling disease progression, thus holding a substantial share within the market landscape.

 Moreover, the increasing prevalence of AMD in the aging population in France, largely due to lifestyle factors and demographic shifts, accentuates the demand for innovative treatment methods across various routes of administration. Accessibility to advanced treatment is further supported by the healthcare infrastructure in France, which emphasizes the significance of both oral and injectable routes in delivering efficient and effective AMD care.Overall, the diversity in the Route of Administration reflects the evolving landscape of therapeutic strategies being employed to combat this pervasive condition.

**Dry Age-Related Macular Degeneration (AMD) Market End Users Insights**

The France Dry Age-Related Macular Degeneration (AMD) Market's End Users segment plays a vital role in shaping the healthcare landscape, primarily comprising hospitals and clinics, diagnostic centers, and academic and research institutes. Hospitals and clinics are essential in diagnosing and managing AMD, often serving as the first point of contact for patients experiencing vision problems. This accessibility fosters early diagnosis and treatment, which is crucial in mitigating the impact of AMD on patients' lives.

Diagnostic centers contribute significantly by providing specialized testing and imaging services, which enhance the accuracy of AMD diagnoses, thereby aiding in tailored treatment strategies.Academic and research institutes are critical as they drive advancements in understanding Dry AMD, exploring novel therapeutic options, and training the next generation of professionals in ophthalmology. 

These facilities not only support clinical practices but also play an influential role in policy-making and healthcare improvements concerning age-related eye diseases. The interconnectedness of these End Users showcases their collective importance in addressing the growing prevalence of AMD within the aging population of France. With the demographics indicating a rising trend in elderly individuals, the End Users segment is positioned to be increasingly significant in providing comprehensive care and innovative solutions for AMD management.

**France Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights**

The France Dry Age-Related Macular Degeneration (AMD) Market is characterized by a dynamic competitive landscape driven by advancements in treatment options and a growing patient population. As the prevalence of dry AMD increases due to the aging demographic, various companies are striving to capture market share through innovative therapies, strategic partnerships, and extensive research. The competitive insights within this market reveal a focus on clinical development, regulatory approvals, and the integration of technology to improve patient outcomes.

Manufacturers are also increasingly emphasizing the importance of education and awareness around age-related eye conditions to enhance patient engagement and promote timely diagnosis.Bayer has established a significant presence in the France Dry Age-Related Macular Degeneration (AMD) Market, leveraging its expertise in ophthalmology and a robust portfolio of treatments. 

The company has invested heavily in research and development, leading to the introduction of effective therapies aimed specifically at managing the symptoms and progression of dry AMD. Bayer's strengths lie in its strong brand recognition, an extensive distribution network, and collaborations with healthcare professionals to ensure optimal delivery of care. Furthermore, Bayer’s commitment to innovation has led to the exploration of combination therapies, enhancing its competitive edge in the French market.Genentech, a key player in the France Dry Age-Related Macular Degeneration (AMD) Market, focuses on offering cutting-edge treatments and solutions specifically designed for AMD patients. 

The company is known for its innovations in monoclonal antibodies and has successfully developed products that target underlying disease mechanisms. Genentech has a significant market presence in France and is recognized for its efforts in clinical research and patient support initiatives. Its collaborative approach leads to mergers and acquisitions that expand its capabilities, contributing to an enhanced product line. With a strong emphasis on patient education and access to therapies, Genentech’s strengths include its reputation for high-quality treatments and a solid pipeline of future developments, positioning it favorably in the competitive landscape of dry AMD management in France.

**Key Companies in the France Dry Age-Related Macular Degeneration (AMD) Market Include:**

- Bayer
- Genentech
- Hoya Corporation
- Paragon Biosciences
- Bausch Health
- Zeiss
- Roche
- Pfizer
- Sanofi
- Novartis
- Santen Pharmaceutical
- Alimera Sciences
- AstraZeneca
- Regeneron Pharmaceuticals

**France Dry Age-Related Macular Degeneration (AMD) Market Industry Developments**

Recent developments in the France Dry Age-Related Macular Degeneration (AMD) Market have shown significant progress from leading companies such as Bayer, Genentech, and Novartis. In September 2023, Genentech received approval in France for a new treatment indication for AMD, reflecting an increase in innovative therapies targeting this condition. Bayer has also been actively enhancing its AMD treatment portfolio through collaborations and research initiatives. 

The market saw substantial growth, with an estimated valuation surge spurred by the aging population in France, which has created a rising demand for effective AMD therapies. Furthermore, important acquisitions have occurred, including Bausch Health's strategic partnership with Santen Pharmaceutical in July 2023 to develop complementary therapies for AMD, which could strengthen its market position. The French government remains focused on eye health initiatives, emphasizing regular screenings and awareness campaigns to improve early detection of AMD. 

This is crucial as the number of individuals affected by dry AMD is expected to increase significantly in the coming years, urging companies like Regeneron Pharmaceuticals and AstraZeneca to expand their research efforts in this area to meet evolving patient needs.

**France Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights**

## Market Drivers

### Rising Aging Population

The France Dry [Age Related Macular Degeneration](https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736) Amd Market is significantly influenced by the increasing aging population. As the demographic landscape shifts, the proportion of individuals aged 65 and older is projected to rise, leading to a higher incidence of age-related diseases, including dry AMD. According to recent statistics, approximately 20% of the population in France is expected to be over 65 by 2030. This demographic trend suggests a growing patient base for dry AMD treatments, thereby driving market demand. Furthermore, the aging population is likely to necessitate enhanced healthcare services and innovative treatment options, which could stimulate growth within the France Dry Age Related Macular Degeneration Amd Market. The implications of this demographic shift are profound, as it may lead to increased healthcare expenditures and a greater focus on preventive measures.

### Emerging Treatment Options

The emergence of novel treatment options is a key driver in the France Dry Age Related Macular Degeneration Amd Market. Recent advancements in pharmacological therapies, including anti-inflammatory agents and neuroprotective drugs, are showing promise in managing dry AMD. Clinical trials are underway to evaluate the efficacy of these new treatments, which could potentially alter the treatment landscape for patients. Additionally, the development of combination therapies that address multiple pathways involved in AMD progression may enhance treatment outcomes. As these innovative therapies gain regulatory approval and enter the market, they are likely to attract significant interest from both healthcare providers and patients. This influx of new treatment options is expected to stimulate growth within the France Dry Age Related Macular Degeneration Amd Market, as patients seek the most effective solutions for managing their condition.

### Increased Awareness and Education

Increased awareness and education regarding dry AMD are pivotal in shaping the France Dry Age Related Macular Degeneration Amd Market. Public health campaigns and educational programs aimed at both healthcare professionals and the general population are essential for promoting understanding of the disease and its risk factors. As awareness grows, individuals are more likely to seek regular eye examinations and early treatment, which can significantly impact disease progression. Furthermore, healthcare providers are increasingly incorporating AMD education into their practices, ensuring that patients receive comprehensive information about their condition. This heightened awareness is expected to lead to an increase in diagnosed cases, thereby expanding the patient base for the France Dry Age Related Macular Degeneration Amd Market. Consequently, the focus on education and awareness is likely to drive demand for innovative treatment options and healthcare services.

### Government Initiatives and Funding

Government initiatives aimed at combating age-related diseases play a crucial role in shaping the France Dry Age Related Macular Degeneration Amd Market. The French government has implemented various health policies that prioritize eye health and funding for research into AMD treatments. For instance, the national health insurance system covers a portion of the costs associated with AMD treatments, making them more accessible to patients. Additionally, public health campaigns aimed at raising awareness about the importance of regular eye examinations are likely to encourage early detection and treatment of dry AMD. This proactive approach not only benefits patients but also alleviates the long-term economic burden on the healthcare system. As a result, government support is expected to foster innovation and investment in the France Dry Age Related Macular Degeneration Amd Market, ultimately enhancing patient outcomes.

### Technological Advancements in Diagnostics

Technological advancements in diagnostic tools are transforming the France Dry Age Related Macular Degeneration Amd Market. Innovations such as [optical coherence tomography](https://www.marketresearchfuture.com/reports/optical-coherence-tomography-market-1328) (OCT) and advanced imaging techniques enable earlier and more accurate detection of dry AMD. These technologies facilitate timely intervention, which is crucial for preserving vision and improving quality of life for patients. The integration of artificial intelligence in diagnostic processes is also emerging, potentially enhancing the efficiency and accuracy of AMD assessments. As these technologies become more widely adopted, they are likely to increase the demand for specialized services and treatments within the France Dry Age Related Macular Degeneration Amd Market. Moreover, the growing emphasis on personalized medicine may lead to tailored treatment plans based on individual diagnostic results, further driving market growth.

## Future Outlook

The Dry Age Related Macular Degeneration market in France is projected to grow at a 7.52% CAGR from 2025 to 2035, driven by increasing aging population and advancements in treatment options.

**New opportunities:**

- Development of telemedicine platforms for remote patient monitoring
- Investment in AI-driven diagnostic tools for early detection
- Expansion of personalized treatment plans based on genetic profiling

By 2035, the market is expected to be robust, driven by innovation and increased patient access.

## Segment Insights

### By Application: Clinical Diagnosis (Largest) vs. Patient Monitoring (Fastest-Growing)

In the France Dry Age Related Macular Degeneration (AMD) Market, the application segment is divided mainly into Clinical Diagnosis, Research and Development, and Patient Monitoring. Among these, Clinical Diagnosis holds the largest market share. This segment is crucial as it is the first point of interaction for patients, involving examinations and tests that determine the presence of AMD. Following closely is the Research and Development segment, which is essential for innovating treatment options, while Patient Monitoring is gaining traction rapidly.

Clinical Diagnosis (Dominant) vs. Patient Monitoring (Emerging)

The Clinical Diagnosis segment is pivotal in the France Dry Age Related Macular Degeneration market, representing a dominant force due to its integral role in identifying the disease early on. It encompasses a variety of testing methods, utilizing advanced imaging and diagnostic tools to ensure accurate results. On the other hand, Patient Monitoring is emerging as a key player in this space, driven by technological advancements and an increasing focus on personalized patient care. This segment emphasizes ongoing assessment and management of patients' conditions, enabling timely interventions. The growing adoption of wearable devices and telemedicine further accelerates its growth, making it an attractive area for investment.

### By Treatment Type: Pharmacological Therapy (Largest) vs. Surgical Intervention (Fastest-Growing)

In the France [Dry Age Related Macular Degeneration Amd](https://www.marketresearchfuture.com/reports/dry-age-related-macular-degeneration-amd-market-10657) Market, the Treatment Type segment showcases diverse approaches, with Pharmacological Therapy holding the largest market share. Patients and healthcare professionals often prefer this segment due to its non-invasive nature and established efficacy. Surgical Intervention, although currently smaller in market share, is gaining traction as advancements in technology improve outcomes and reduce recovery times.

The growth trends in this segment are driven by increasing awareness and diagnosis of AMD, as well as ongoing research into effective treatment methodologies. Emerging therapies, particularly in pharmacological options, are being developed to provide better management of symptoms. Additionally, the rising geriatric population in France further propels demand for both pharmacological and surgical treatments, urging innovations and improvements in existing therapies.

Pharmacological Therapy (Dominant) vs. Nutritional Supplements (Emerging)

Pharmacological Therapy continues to dominate the France Dry Age Related Macular Degeneration Amd Market due to established treatment protocols that effectively manage the condition. This approach utilizes various medications that target the underlying processes of AMD, ensuring stability and improvement of vision quality for patients. On the other hand, Nutritional Supplements are becoming an emerging segment, appealing to health-conscious consumers seeking preventive measures. These supplements, often containing antioxidants and vitamins, play a supportive role in overall eye health. As research increasingly backs the efficacy of specific nutrients in delaying AMD progression, this segment is expected to grow, catering to a market focused on holistic health and wellness.

### By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the France Dry Age Related Macular Degeneration (AMD) market, age groups significantly influence the prevalence and management of AMD. The largest segment is the elderly population, particularly those aged 65 and above, who show the highest occurrence of this condition. This demographic accounts for the majority of AMD patients in France, reflecting not only the age-related nature of the disease but also its increased detection among older individuals due to enhanced screening practices. 
The gender distribution within AMD patients reveals a fascinating trend, with a growing number of females being diagnosed. Factors such as longevity in women and genetic predispositions contribute to this increase, making gender an integral aspect of AMD demographics. As awareness and screening efforts focus on women, this segment is poised to expand rapidly, reflecting changing healthcare dynamics in the country.

Age Group: 65+ (Dominant) vs. Gender: Female (Emerging)

The age group of 65 and above is the dominant segment within the France Dry Age Related Macular Degeneration market, primarily due to the natural escalation of AMD with advancing age. This demographic typically requires a tailored approach to management and treatment, given their unique healthcare needs and comorbidities. On the other hand, the emerging female demographic in the AMD market is highlighting a shift in health patterns. As women are at a higher risk for AMD due to genetic and age factors, their increasing representation in the patient pool necessitates a focused approach in treatment protocols and awareness campaigns. This evolving landscape indicates a vital need for specialized care tailored to the distinct characteristics of both dominant and emerging patient groups.

### By Distribution Channel: Hospital Pharmacies (Largest) vs. Online Pharmacies (Fastest-Growing)

In the France Dry Age Related Macular Degeneration (AMD) market, the distribution channels exhibit a varied share among hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies hold the largest proportion of market share due to their integration with healthcare services and direct physician referrals. Retail pharmacies also play a significant role; however, they face stiff competition from emerging online platforms that enhance accessibility for patients seeking AMD treatments.

Hospital Pharmacies (Dominant) vs. Online Pharmacies (Emerging)

Hospital pharmacies dominate the distribution landscape for dry AMD treatments in France, primarily due to their established patient trust, accessibility within the healthcare network, and the ability to provide comprehensive patient care through supportive services. Meanwhile, online pharmacies are emerging as a vital part of this market, driven by consumers' preference for convenience and direct access to specialized AMD medications. This segment offers competitive pricing and the ability to deliver medications directly to patients, fostering growth as they adapt to increasingly digital consumer behavior. Both channels play distinct yet complementary roles in the larger framework of AMD treatment accessibility.

## Competitive Benchmarking

The Dry Age Related Macular Degeneration Amd Market in France is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Novartis (FR), Roche (FR), and Regeneron Pharmaceuticals (FR) are actively pursuing strategies that emphasize research and development, aiming to enhance their product offerings and market share. Novartis (FR) has focused on expanding its portfolio through innovative therapies, while Roche (FR) has been investing in digital health solutions to improve patient outcomes. Regeneron Pharmaceuticals (FR) appears to be leveraging its strong pipeline of treatments to solidify its position in the market, indicating a trend towards specialization and targeted therapies.

The market structure is moderately fragmented, with several players vying for dominance. Companies are adopting various business tactics, such as localizing manufacturing and optimizing supply chains, to enhance operational efficiency. This competitive environment is influenced by the collective actions of these key players, who are not only competing on product efficacy but also on the ability to deliver solutions that meet the evolving needs of patients and healthcare providers.

In December 2025, Novartis (FR) announced a strategic partnership with a leading digital health company to develop an AI-driven platform aimed at improving the management of AMD. This collaboration is expected to enhance patient engagement and adherence to treatment protocols, thereby potentially increasing the effectiveness of their therapies. Such initiatives reflect a broader trend towards integrating technology into healthcare solutions, which may redefine patient care in the AMD space.

In November 2025, Roche (FR) launched a new clinical trial for its innovative gene therapy targeting dry AMD. This trial is significant as it represents a shift towards personalized medicine, which could offer more effective treatment options for patients. The implications of this development are profound, as successful outcomes could position Roche (FR) as a leader in the next generation of AMD therapies, thereby reshaping competitive dynamics in the market.

In October 2025, Regeneron Pharmaceuticals (FR) expanded its research collaboration with a prominent academic institution to explore novel therapeutic targets for AMD. This strategic move underscores the importance of academic partnerships in driving innovation and may lead to breakthroughs that enhance the company's product pipeline. Such collaborations are likely to foster a culture of innovation that is essential for maintaining a competitive edge in the rapidly evolving AMD market.

As of January 2026, the competitive trends in the Dry Age Related Macular Degeneration Amd Market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in addressing complex healthcare challenges. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately lead to improved patient outcomes and a more sustainable market environment.

## Recent News & Developments

Recent developments in the France Dry Age-Related Macular Degeneration (AMD) Market have shown significant progress from leading companies such as Bayer, Genentech, and Novartis. In September 2023, Genentech received approval in France for a new treatment indication for AMD, reflecting an increase in innovative therapies targeting this condition. Bayer has also been actively enhancing its AMD treatment portfolio through collaborations and research initiatives. 

The market saw substantial growth, with an estimated valuation surge spurred by the aging population in France, which has created a rising demand for effective AMD therapies. Furthermore, important acquisitions have occurred, including Bausch Health's strategic partnership with Santen Pharmaceutical in July 2023 to develop complementary therapies for AMD, which could strengthen its market position. The French government remains focused on eye health initiatives, emphasizing regular screenings and awareness campaigns to improve early detection of AMD. 

This is crucial as the number of individuals affected by dry AMD is expected to increase significantly in the coming years, urging companies like Regeneron Pharmaceuticals and AstraZeneca to expand their research efforts in this area to meet evolving patient needs.

## Report Scope

| MARKET SIZE 2024 | 239.9(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 259.81(USD Million) |
| MARKET SIZE 2035 | 532.73(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.52% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Novartis (FR), Roche (FR), Regeneron Pharmaceuticals (FR), Bayer (FR), Allergan (FR), Apellis Pharmaceuticals (FR), Santen Pharmaceutical (FR), Horizon Therapeutics (FR) |
| Segments Covered | Application, Treatment Type, Patient Demographics, Distribution Channel |
| Key Market Opportunities | Emergence of innovative therapies and diagnostic tools in the France Dry Age Related Macular Degeneration Amd Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition in France's Dry Age Related Macular Degeneration market. |
| Countries Covered | France |

## Frequently Asked Questions

**Q: What is the current market valuation of the France Dry Age Related Macular Degeneration AMD market?**
A: The market valuation was 239.9 USD Million in 2024.

**Q: What is the projected market size for the France Dry Age Related Macular Degeneration AMD market by 2035?**
A: The projected valuation for 2035 is 532.73 USD Million.

**Q: What is the expected CAGR for the France Dry Age Related Macular Degeneration AMD market during the forecast period?**
A: The expected CAGR during the forecast period 2025 - 2035 is 7.52%.

**Q: Which companies are the key players in the France Dry Age Related Macular Degeneration AMD market?**
A: Key players include Novartis, Roche, Regeneron Pharmaceuticals, Bayer, Allergan, Apellis Pharmaceuticals, Santen Pharmaceutical, and Horizon Therapeutics.

**Q: How does the market segment by application perform in terms of valuation?**
A: The Clinical Diagnosis segment was valued at 80.0 to 180.0 USD Million, while Patient Monitoring reached 89.9 to 202.73 USD Million.

**Q: What are the treatment types contributing to the France Dry Age Related Macular Degeneration AMD market?**
A: Pharmacological Therapy was valued at 100.0 to 230.0 USD Million, and Nutritional Supplements ranged from 69.9 to 152.73 USD Million.

**Q: How is the market segmented by patient demographics?**
A: The Age Group segment was valued at 80.0 to 180.0 USD Million, and Gender reached 70.0 to 160.0 USD Million.

**Q: What distribution channels are utilized in the France Dry Age Related Macular Degeneration AMD market?**
A: Hospital Pharmacies were valued at 95.96 to 215.0 USD Million, while Online Pharmacies ranged from 72.02 to 157.73 USD Million.

**Q: What trends are observed in the research and development segment of the market?**
A: The Research and Development segment was valued at 70.0 to 150.0 USD Million, indicating a focus on innovation.

**Q: How does the socioeconomic status of patients impact the market?**
A: The Socioeconomic Status segment was valued at 89.9 to 192.73 USD Million, suggesting its relevance in market dynamics.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/france-dry-age-related-macular-degeneration-market-44898*